Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.

Trial Details

NCT ID
NCT06793553
Phase
PHASE2
Sponsor
Japan Breast Cancer Research Group
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Induction therapy
Locations (sample)
  • Koto-ku, 3-8-31, Tokyo, Japan

Key Eligibility Criteria

  • Diagnosed with metastatic recurrent or unresectable advanced TNBC
  • Documented PD-L1 positivity (SP142 IC ≥ 1) confirmed by local assessment of the most recent tumor sample or an archival tumor sample.
  • In the case of patients who were candidates for curative treatment, the duration from the completion of the curative treatment {date of surgery for…
  • ECOG PS 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →